Trial · NCT06775314
The Effectiveness and Safety of Cleanser Containing Triethyl Citrate, Pyruvic Acid, Combination Cream Containing Triethyl Citrate, Ethyl Linoleate, GT Peptide-10, Salicylic Acid 0,5%, Zinc Lactate, Hyaluronic Acid and Spot Cream Containing Triethyl Citrate, Ethyl Linoleate, GT Peptide-10, Honokiol
NCT06775314, Phase 3, Not yet recruiting, Dr.dr.Irma Bernadette, SpKK (K)
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effectiveness and Safety of Cleanser Containing Triethyl Citrate, Pyruvic Acid, Combination Cream Containing Triethyl Citrate, Ethyl Linoleate, GT Peptide-10, Salicylic Acid 0,5%, Zinc Lactate, Hyaluronic Acid and Spot Cream Containing Triethyl Citrate, Ethyl Linoleate, GT Peptide-10, Honokiol. Trials, record NCT06775314. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06775314
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
The Effectiveness and Safety of Cleanser Containing Triethyl Citrate, Pyruvic Acid, Combination Cream Containing Triethyl Citrate, Ethyl Linoleate, GT Peptide-10, Salicylic Acid 0,5%, Zinc Lactate, Hyaluronic Acid and Spot Cream Containing Triethyl Citrate, Ethyl Linoleate, GT Peptide-10, Honokiol
- NCT number
- NCT06775314
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 102 participants, estimated
- Lead sponsor
- Dr.dr.Irma Bernadette, SpKK (K)
- Conditions
- Acne Vulgaris
- Interventions
- Cleanser, Combination cream, spot cream, Adapalene 0,1% cream, placebo cleanser, placebo cream combination, placebo spot cream
- First posted
- 2025-01-15
- Last updated
- 2025-01-16
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change of acne severity | Re-evaluation on day 28, 56 and 84 of therapy | Based on global acne severity scale (GEA score). On a scale of 0-5, 0 indicates no lesion, while 5 indicates very severy acne |
| Primary | Change of acne severity | Re-evaluation on day 28, 56 and 84 of therapy | Based on Indonesia Acne Expert Meeting scale (IAEM scale). the scale consists of mild, moderate and severe. |
| Primary | total of inflammation lesion and non inflammation lesion | Re-evaluation on day 28, 56 and 84 of therapy | The total lesion will be examined by dermatologist |
| Primary | acne sequelae | Re-evaluation on day 28, 56 and 84 of therapy | The acne sequelae will be examined by dermatologist |
| Primary | Quality of life | Re-evaluation on day 28, 56 and 84 of therapy | Based on acne quality of life (Acne-QoL). Total score of acne-QoL is 0-114, the higher score interprets better quality of life of acne vulgaris patient |
| Primary | Erythema severity | Re-evaluation on day 28, 56 and 84 of therapy | based on clinician erythema assessment scale (CEA scale). on the scale of 0-4. 0 indicates no erythema, while 4 indicates severe erythema |
| Primary | Facial analysis | Re-evaluation on day 28, 56 and 84 of therapy | The facial analysis will be done by using janus facial analysis system |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06775314
GET https://conductscience.org/api/trials/v1/NCT06775314/registered